Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Diagnosing Skin Disease in Patients with Dark Skin

Thomas R. Collins  |  November 23, 2024

“When you compare this to what we’re taught to look for in the heliotriope rash, it can be easy to miss—and indeed this was missed for a long time,” said Dr. Okoye.

A “trick” she uses to more easily identify erythema in people with darker skin is to examine them with a blue background—with a blue sheet of paper or blue fabric—which “usually makes the redness stand out a little bit more.” She also said that photos taken with a phone can sometimes allow a clinician to see redness even better than they can see with their own eyes.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

She also said that, due to a crosstalk between melanocytes and fibroblasts, hypopigmentation or depigmentation can be a sign of fibrosis or scarring.1

“I think I see this the most, in the salt-and-pepper pigmentation of scleroderma, where the areas of fibrosis can lose pigment altogether,” she said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pigmentation can also be used to track someone’s response to therapy, she said.

Focus on Scleroderma

Dr. Hummers

Dr. Hummers

Dr. Hummers said that many diseases can look a lot like scleroderma at first blush, forcing clinicians to be alert to telling distinctions.2

“Most of these diagnoses are clinically distinguishable without biopsy if you just think about some of these things,” she said.

She showed a photo of a hand that had some skin tightness and some pigmentary changes. “If you just looked at that hand, we would often say, ‘Well, that looks like systemic sclerosis,’” she said. “But that person has scleromyxedema.”

This disease, she said, is the “most scleroderma-like” of the mimics, with a distribution that is very similar but with the exceptions that it involves prominent skin changes around the ear, almost always with papules, and it does not spare the back, while scleroderma does. The skin quality resembles scleroderma as well, but with a “papular quality” and with the papules sometimes coalescing, leaving the skin just feeling thick, she said.

According to Dr. Hummers, a biopsy may help, but if one is ordered, a mucin stain should be specifically requested.

Diffuse scleroderma involves nearly the whole body, but it spares the mid-back, almost always spreads in a distal to proximal direction and always involves the fingers. The skin quality is thick and waxy and difficult to pinch, she said.

She emphasized the importance of including RNA polymerase III in labs becauseit’s linked to the risk of progression, the risk of a renal crisis and the presence of cancer.

Page: 1 2 3 | Single Page
Share: 

Filed under:ACR ConvergenceConditionsMeeting ReportsPsoriatic ArthritisSystemic Sclerosis Tagged with:ACR Convergence 2024

Related Articles

    A Case of Eosinophilic Fasciitis Presenting with Pansclerotic Morphea

    May 17, 2019

    Eosinophilic fasciitis generally presents with the acute onset of edema followed by progressive skin induration in the setting of hypergammaglobulinemia, an elevated erythrocyte sedimentation rate (ESR) and peripheral eosinophilia in 63–93% of patients.1,2 Skin involvement is typically limited to 20.1% of total body surface area and most commonly involves the extremities symmetrically.1,3 The condition was…

    Kamolrat/SHUTTERSTOCK.COM

    Eosinophilia: A Diagnostic Evaluation Guide for Rheumatologists

    June 15, 2015

    Clinical Vignette A 45-year-old woman with long-standing asthma and chronic sinusitis has new-onset peripheral neuropathy, arthralgias, fatigue, progressive dyspnea and a nonproductive cough. She has never smoked and has no environmental exposures. Her medications include an albuterol metered-dose inhaler (which she uses daily); an inhaled corticosteroid, montelukast; and ibuprofen (which she takes occasionally). She is…

    Fibrotic Diseases of the Retroperitoneum & Skin, & Rare Scleroderma Mimics

    January 19, 2018

    SAN DIEGO—Fibrosis affects all organ systems, but isn’t always systemic sclerosis. Experts on less common forms discussed patient presentations, diagnosis and treatment at the 2017 ACR/ARHP Annual Meeting in San Diego on Nov. 6. Retroperitoneal Fibrosis Formerly called Ormond’s disease, retroperitoneal fibrosis (RPF) is usually an IgG4-related disease, but has some unique characteristics, said John…

    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    February 16, 2021

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences